News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Insider Information

Epigenomics adjusts 2015 outlook after FDA response letter

Ad hoc Releases 2016 Pursuant to § 15 WpHG (German Securities Trading Act) PDF 74 KB Berlin, Germany, November 4, 2015 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) adjusts its financial outlook for fiscal year 2015 following the FDA response letter on the Company’s lead product Epi proColon®. As communicated in […]

Read more

FDA requests further data for approval of Epigenomics’ blood-based colorectal cancer screening test

Ad hoc Releases 2016 Pursuant to § 15 WpHG (German Securities Trading Act) PDF 189 KB   Berlin, Germany, November 4, 2015 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX, ISIN: DE000A11QW50), announces that it has received a response letter from the U.S. Food and Drug Administration (FDA) in relation to its premarket approval […]

Read more

Ad-hoc: Epigenomics Reaches 99.5 % Adherence for Epi proColon® in ADMIT Study

Ad hoc Releases 2016 Pursuant to § 15 WpHG (German Securities Trading Act) PDF 58 KB   Berlin – Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) announces results from the ADMIT trial (ADherence to Minimally Invasive Testing – NCT02251782) for its non-invasive blood-based test for colorectal cancer (CRC) screening, Epi proColon®. The study demonstrated […]

Read more

Ad hoc: Epigenomics and BioChain Announce Approval of Epi proColon® in China

PDF 145 KB   Berlin (Germany), Germantown, MD, and Newark, CA (U.S.A.), Beijing (China) – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, and BioChain, a leading clinical diagnostics company in cancer and genetic testing in China and the U.S.A., announced today that the China Food and Drug Administration […]

Read more

Ad hoc: Epigenomics raises USD 5.3 million from its strategic commercialization partner BioChain

Berlin (Germany) and Germantown (USA), October 16, 2014 – Epigenomics AG (ISIN: DE000A11QW50, OTCQX: EPGNY) announces today that the Company is raising USD 5.3 million (EUR 4.2 million) in a share capital increase. BioChain Institute, Inc. will subscribe a total of 1,351,089 Epigenomics shares which will be issued under exclusion of the statutory subscription right […]

Read more

FDA Issues Response Letter for Epigenomics’ Colorectal Cancer Screening Blood Test Epi proColon® Requesting Further Data Pre-Approval

PDF 273 KB   Berlin (Germany) and Germantown, MD (U.S.A.) – Epigenomics AG (ISIN: DE000A1K0516, OTCQX: EPGNY) today announced that it has received a response letter from the U.S. Food and Drug Administration (FDA) in relation to its premarket approval (PMA) application for the Company’s blood-based colorectal cancer (CRC) screening test Epi proColon®. In its […]

Read more